Compare Organon & Co. Common Stock (OGN) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Nasdaq100 ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Nasdaq100 ETF trades at $720.04 (market cap $506.12B). The key difference: Nasdaq100 ETF is far larger — about 140.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Nasdaq100 ETF for 163 Days on average.
| OGN | QQQ | |
|---|---|---|
Market Cap | $3.61B | $506.12B |
Volume | 1,808,049 | 51,534,028 |
Sector | Health | — |
52-Week High | $13.81 | $759.66 |
52-Week Low | $5.70 | $558.34 |
Typical Hold Time | 0 Days | 163 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
QQQ trades at $743.57, down 0.32% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF shows mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights QQQ's strong decade-long performance and ongoing innovation with new international ETF launches, though concerns about AI market valuations and expense ratios compared to competitors like QQQM persist.
Outlook remains cautiously optimistic given QQQ's tech-heavy exposure and AI-driven growth potential, but risks include market volatility from Fed rate hikes, high concentration in tech stocks, and valuation concerns. The dividend of $0.75 payable in October 2026 provides minor income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
